Pediatric and Geriatric Clinical Trials

Understanding Assent vs Consent in Pediatric Clinical Trials

Posted on digi By digi

In pediatric clinical trials, obtaining both informed consent and assent is a cornerstone of ethical compliance. While informed consent is a legally binding agreement provided by a parent or legal guardian, assent is the child’s affirmative agreement to participate, given in language and context appropriate to their developmental stage. Internationally recognized frameworks such as ICH E6(R2) Good Clinical Practice emphasize that children should be involved in decision-making to the extent that their maturity and comprehension allow.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials

Ethics Committee Review for Vulnerable Populations in Clinical Trials

Posted on digi By digi

Ethics Committees (ECs), also known as Institutional Review Boards (IRBs), play a critical role in safeguarding vulnerable populations in clinical trials. Vulnerable groups — such as children, the elderly, pregnant women, prisoners, or individuals with cognitive impairments — face higher risks of coercion or exploitation. Regulatory frameworks, including the ICH E6(R2) GCP guidelines, the U.S. 45 CFR 46 Subparts B-D, and the EU Clinical Trials Regulation, mandate heightened scrutiny when these populations are enrolled.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials

Ethics Committee Review for Vulnerable Populations in Clinical Trials

Posted on digi By digi

Ethics Committees (ECs), also known as Institutional Review Boards (IRBs), serve as the primary guardians of participant rights and welfare in clinical trials. When studies involve vulnerable populations—such as children, the elderly, pregnant women, prisoners, refugees, or individuals with cognitive impairments—this oversight becomes even more critical. These groups may have limited capacity to give fully informed consent or may be at higher risk of coercion.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials

Managing Parental Consent and Minor Assent in Pediatric Clinical Trials

Posted on digi By digi

In pediatric clinical research, two separate but complementary processes are essential: parental consent and minor assent. Parental consent is the legally required authorization from a child’s parent or legal guardian, while minor assent is the child’s affirmative agreement to participate, provided in language they can understand. The ICH E6(R2) Good Clinical Practice guidelines and country-specific regulations (e.g., 21 CFR Part 50 Subpart D in the U.S., EU Clinical Trials Regulation No 536/2014) clearly outline when and how these must be obtained.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials

Balancing Risk and Benefit in Elderly Trial Participants

Posted on digi By digi

The global population is aging rapidly, and the inclusion of elderly participants in clinical trials has become essential to ensure therapies are effective and safe in this demographic. Regulatory agencies, including the European Medicines Agency and the U.S. Food and Drug Administration, emphasize the need for trials to reflect the age range of the target patient population. The ICH E7 guideline specifically addresses “Studies in Support of Special Populations: Geriatrics,” recommending a representative proportion of elderly participants in Phase II and III trials.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials

Ethical Frameworks for Multi-Age Inclusion in Clinical Trials

Posted on digi By digi

Clinical trials increasingly strive to include participants across the lifespan — from children to elderly adults — to generate data that reflects real-world patient populations. This shift aligns with global regulatory encouragement for inclusive research. However, inclusion of multiple age groups introduces unique ethical complexities, especially regarding informed consent, risk-benefit assessment, and age-specific safeguards.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials

Addressing Age-Related Cognitive Impairment in Clinical Trials

Posted on digi By digi

Age-related cognitive impairment ranges from mild memory loss to severe dementia and is prevalent among elderly trial participants. It poses significant ethical and operational challenges for clinical research, primarily in obtaining and maintaining valid informed consent. According to FDA guidance, sponsors must ensure that participants comprehend trial-related information at enrollment and throughout the study, especially when cognitive decline is progressive.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials

Involving Caregivers in Clinical Trial Decision-Making

Posted on digi By digi

Caregivers—whether parents, legal guardians, or family members—play a critical role in ensuring ethical participation, compliance, and safety for vulnerable clinical trial participants. In pediatric research, caregivers provide legal consent and help interpret study requirements for children. In geriatric trials, particularly those involving cognitive decline, caregivers often act as legally authorized representatives (LARs) and provide ongoing support throughout the study.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials

Cultural Considerations in Pediatric Ethics

Posted on digi By digi

In pediatric clinical research, cultural considerations extend beyond language translation—they shape parental decision-making, community trust, and the child’s assent process. Different societies have unique norms regarding children’s autonomy, parental authority, and healthcare practices. For instance, in some cultures, extended family members are heavily involved in healthcare decisions, while in others, only the nuclear family is consulted. Researchers must be aware of these nuances to uphold ethical integrity and regulatory compliance.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials

Compensation Ethics for Geriatric Participation

Posted on digi By digi

Geriatric participants often face unique challenges in clinical trial participation, such as mobility issues, higher dependency on caregivers, and fixed incomes. While compensation can offset participation-related costs, it must be carefully designed to avoid undue influence. This is especially important because elderly populations may be more susceptible to viewing compensation as a primary incentive, potentially overshadowing risk considerations.
Click to read the full article.

Ethical Considerations, Pediatric and Geriatric Clinical Trials